New Strategy Nets Biomarkers for AD, and More
A new strategy for detecting serum antibodies could have important ramifications for Alzheimer’s disease diagnostics...
ALL NEWS
463 RESULTS
Sort By:
- Most Recent
- Most Commented
Research Brief: How Normal Is Normal? ADNI Data Begs The Question
Researchers report stark differences among cognitively normal people enrolled in the Alzheimer’s Disease Neuroimaging Initiative...
DC: Biomarkers, Parkinson’s—CAMD Needs All Hands on Deck
Speakers focused on the Coalition Against Major Diseases’ goal of garnering approval for biomarkers in AD drug development...
San Diego: Pre-AD Brain Changes May Allow Early Diagnosis
In an ideal future, physicians would diagnose people with incipient Alzheimer’s disease long before memory problems appear...
London: What, No Argument? Speakers Agree on Trials for Familial AD
Part 2 of Alzforum’s coverage continues with what scientists from inside and outside DIAN said about the prospect of such pre-symptomatic trials...
ApoE2 Carriers Have Less Brain Atrophy, AD Pathology in Spinal Fluid
The few people who have an ApoE2 allele enjoy reduced risk of late-onset Alzheimer’s disease...
Indianapolis: Neuroimaging Opens Window to Disease, Better Diagnosis
Frontotemporal dementias pose a challenge for diagnosis because numerous overlapping clinical syndromes are associated with the disease...
An Oligomer Test for PD—Could One for AD Be Close Behind?
Small, soluble oligomers of amyloid-β (Aβ) are now widely believed to be the most toxic form of the peptide...
PPMI: Brain Imaging To Reveal Preclinical Parkinson’s Signature?
PPMI was launched in July with hopes of identifying a biomarker, or set of markers, that tracks the natural course of Parkinson disease...
PPMI: Parkinson's Field’s Answer to ADNI
One of the great challenges with developing treatments for neurodegenerative disorders stems from the capricious nature of disease progression...
Common Ground: Is Aβ the Foundation for Multiple Dementias?
The majority of patients with Parkinson disease eventually develop dementia, but what pathology underlies this decline?...
Triple Confirmation: AD Footprint in CSF of Cognitively Normal People
In clinical research, a first-time finding may rouse intrigue, but it’s generally independent confirmations of the data that give them potential to leave an indelible mark...
Honolulu: Biomarker Profiles That Spell Trouble for ‘Normals’?
Scientists have drafted a new set of diagnostic research criteria redefining AD as a condition that develops decades prior to obvious symptoms...
Revised Criteria for Preclinical AD, Exactly as Presented
Three workgroups of clinicians from the U.S. and Europe offered new guidelines for the diagnosis of AD...
Noisy Response Greets Revised Diagnostic Criteria for AD
Three groups presented results of their ongoing effort to incorporate scientific advances of the past quarter-century into a revision of the current diagnostic AD criteria...